| |||||||||

Industry (USD) Annual | ||||||||
|---|---|---|---|---|---|---|---|---|
| FISCAL YEAR ENDING |
|
31-DEC 2004 |
31-DEC 2005 |
31-DEC 2006 |
31-DEC 2007 |
31-DEC 2008 |
||
| Operating Income | -413M | 5.62B | 7.56B | 8.63B | 6.11B | |||
| Gross Profit | 16.2B | 27.1B | 31.7B | 33.1B | 33.3B | |||
| Total Revenues | 20.4B | 33.7B | 38.9B | 42.7B | 40.1B | |||
| Net Income | -4.89B | 2.67B | 5.29B | 7.69B | 5.35B | |||
| Gross Margin | 75.9% | 76.7% | 77.2% | 77.1% | 77.9% | |||
| Research and Development Expense | 2.39B | 4.04B | 4.43B | 4.54B | 4.58B | |||
| R&D/Sales Ratio | 16.1% | 14.8% | 15.6% | 16.2% | 16.6% | |||
| Number of Drugs | 0 | 127 | 125 | 113 | 0 | |||
| Number of Drugs in Phase I | 0 | 24.0 | 24.0 | 21.0 | 20.0 | |||
| Number of Drugs in Phase II | 0 | 30.0 | 29.0 | 19.0 | 18.0 | |||
| Number of Drugs in Phase III | 0 | 16.0 | 18.0 | 18.0 | 23.0 | |||
| Number of Drug Approvals | 0 | 20.0 | 22.0 | 17.0 | 0 | |||
| New Drug Applications | 0 | 35.0 | 31.0 | 27.0 | 0 | |||
| ||||||